| DC Field | Value | Language |
|---|
| dc.contributor.author | Khokhlov, A. L. | - |
| dc.contributor.author | Yaichkov, I. I. | - |
| dc.contributor.author | Shetnev, A. A. | - |
| dc.contributor.author | Korsakov, M. K. | - |
| dc.contributor.author | Volkhin, N. N. | - |
| dc.date.accessioned | 2026-03-18T13:05:51Z | - |
| dc.date.available | 2026-03-18T13:05:51Z | - |
| dc.date.issued | 2025 | - |
| dc.identifier.citation | The excretion study of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide in rats / A.L. Khokhlov, I.I. Yaichkov, A.A. Shetnev [et al.] // Research Results in Pharmacology. - 2025. - Vol.11, №4.-P. 187-198. - Doi: 10.18413/rrpharmacology.11.524. - Refer.: p. 197-198. | ru |
| dc.identifier.uri | http://dspace.bsuedu.ru/handle/123456789/66353 | - |
| dc.description.abstract | The 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide (ODASA) is a new carbonic anhydrase II inhibitor for open-angle glaucoma treatment, but the excretion study of this compound has not been performed yet. Aim: Calculation of excretion parameters of ODASA and its metabolites in urine and feces in rats | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | urine | ru |
| dc.subject | feces | ru |
| dc.subject | stabilization | ru |
| dc.subject | validation | ru |
| dc.subject | pharmacokinetics | ru |
| dc.subject | excretion | ru |
| dc.subject | rats | ru |
| dc.subject | carbonic anhydrase II inhibitor, N-hydroxysulfonamide | ru |
| dc.title | The excretion study of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide in rats | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 11, № 4
|
